查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1613136

先天性高胰島素血症治療藥物市場：按適應症類型、治療方法、給藥途徑、分銷管道和最終用戶分類 - 全球預測 2025-2030

Congenital Hyperinsulinism Treatment Market by Indication Type, Treatment, Route of Administration, Distribution Channel, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

先天性高胰島素血症治療藥物市場2023年估值為1.8253億美元，預計2024年將達1.922億美元，複合年成長率為5.61%，預計2030年將達220萬美元，預計將達到6764萬美元。

先天性高胰島素血症（CHI）治療涉及解決以胰島素過度分泌並導致持續低血糖為特徵的疾病。由於這種疾病主要影響嬰幼兒和兒童，因此早期診斷和治療對於預防神經系統併發症非常重要。目前，治療包括醫療管理，例如使用二氮嗪和Octreotide等藥物，在嚴重的情況下，還包括手術選擇，例如切除術。由於嚴重程度各異，目前的治療方法療效有限，並且具有顯著的副作用，因此迫切需要改進 CHI 的治療。最終用途範圍主要包括醫院、專科診所和研究機構。市場成長的推動因素包括為了更好地了解 CHI 而進行的基因研究的進步、醫療保健支出的增加以及診斷設施普及率的提高等。新的發展機會在於基因治療、個人化醫療解決方案和創新藥物輸送系統的發展。此外，生技公司和研究機構之間探索新治療途徑的合作前景廣闊，應積極推廣。然而，市場擴張面臨挑戰，包括治療成本高、新興市場對 CHI 的認知度低以及與新治療方法核准相關的監管障礙。此外，CHI 的稀有性限制了市場規模，一些製藥公司不願投資研發。為了克服這些限制，公司應該專注於診斷和非侵入性治療方法的創新，在某些情況下，人工智慧和巨量資料分析可以改善臨床結果和成本效率。此外，促進患者的倡導和參與將有助於提高意識提升和政府政策來支持市場成長。市場的利基但不斷發展的性質強調研究和合作夥伴關係，利用精準醫學來提供更有針對性、更有效和可客製化的治療方法。

主要市場統計
基準年[2023] 1.8253 億美元
預計年份 [2024] 1.922 億美元
預測年份 [2030] 2.6764億美元
複合年成長率（%） 5.61%

市場動態：快速發展的先天性高胰島素血症治療市場的關鍵市場洞察

先天性高胰島素血症藥物市場正因供需的動態交互作用而轉變。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 先天性高胰島素血症盛行率增加
    • 政府努力促進先天性胰島素分泌過多的診斷
  • 市場限制因素
    • 先天性高胰島素血症的報銷限制
  • 市場機會
    • 持續研究和開發以推進先天性胰島素分泌過多的治療
    • 治療先天性胰島素分泌過多症的新核准
  • 市場挑戰
    • 診斷挑戰和治療中潛在的併發症

波特五力：駕馭先天性高胰島素血症藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解先天性高胰島素血症治療藥物市場的外部影響

外部宏觀環境因素在塑造先天性高胰島素血症治療藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解先天性高胰島素血症治療藥物市場的競爭狀況

先天性高胰島素血症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣先天性高胰島素血症治療市場供應商的績效評估

FPNV 定位矩陣是評估先天性高胰島素血症治療藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，繪製先天性高胰島素血症治療藥物市場的成功之路

先天性高胰島素血症治療藥物市場的策略分析對於希望加強在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 先天性高胰島素血症盛行率增加
      • 政府努力促進先天性高胰島素血症的診斷
    • 抑制因素
      • 先天性高胰島素血症的報銷有限
    • 機會
      • 持續研究和開發以推進先天性高胰島素血症的治療
      • 治療先天性高胰島素血症的核准取得進展
    • 任務
      • 診斷挑戰和可能的治療併發症
  • 市場區隔分析
    • 適應症類型：非典型CHI的治療需要更個人化的方法
    • 最終使用者：先天性高胰島素血症在醫院需要多種治療方法
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章先天性高胰島素血症治療藥物市場（依適應症類型）

  • 非典型先天性高胰島素血症
  • 瀰漫性先天性高胰島素血症
  • 局部先天性高胰島素血症

第7章先天性高胰島素血症治療藥物市場（依治療）

  • 膳食管理
  • 藥品
    • 二氮嗪
    • 升糖素
    • 硝苯地平
    • Octreotide
  • 手術介入

第8章先天性高胰島素血症治療藥物市場：依給藥途徑

  • 口服
  • 胃腸外的

第9章先天性高胰島素血症治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章先天性高胰島素血症治療藥物市場：依最終用戶分類

  • 門診手術中心
  • 醫院
  • 專科診所

第11章 北美和南美先天性高胰島素血症治療藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區先天性高胰島素血症治療藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東和非洲先天性高胰島素血症治療藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • C-Path 和先天性高胰島素症國際宣布資料共用協議
    • Zealand Pharma 向美國FDA 提交用於治療先天性高胰島素血症的升糖素新藥申請
    • Rhythm Pharmaceuticals 宣布收購 Xinvento BV 和臨床實驗藥物組合
  • 戰略分析和建議

公司名單

  • Crinetics Pharmaceuticals, Inc.
  • Eiger Biopharmaceuticals Inc.
  • Hanmi Pharmaceutical Company
  • Hua Medicine（Shanghai）Co., Ltd.
  • Novartis AG
  • Rezolute, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • Twist Bioscience Corporation
  • Xeris Biopharma Holdings, Inc.
  • XOMA Corporation
  • Zealand Pharma A/S
Product Code: MRR-F97DD5A7D994

The Congenital Hyperinsulinism Treatment Market was valued at USD 182.53 million in 2023, expected to reach USD 192.20 million in 2024, and is projected to grow at a CAGR of 5.61%, to USD 267.64 million by 2030.

Congenital hyperinsulinism (CHI) treatment involves addressing a condition characterized by excessive insulin secretion, leading to persistent hypoglycemia. This disorder predominantly affects infants and children, making early diagnosis and treatment crucial to prevent neurological complications. Currently, treatment encompasses medical management, such as the use of drugs like diazoxide and octreotide, and surgical options like pancreatectomy in severe cases. The necessity for improved CHI treatments is high due to the variability in the disease's severity and the limited efficacy and significant side effects of current therapies. The end-use scope primarily involves hospitals, specialty clinics, and research institutions. Market growth is driven by factors such as advancements in genetic research for better CHI understanding, increasing healthcare expenditure, and a rising prevalence of diagnostic facilities. Emerging opportunities lie in developing gene therapies, personalized medicine solutions, and innovative drug delivery systems. Moreover, collaborations between biotechnology companies and research institutions to explore novel therapeutic pathways show promise and should be actively pursued. However, market expansion faces challenges including the high cost of treatment, limited awareness of CHI in developing regions, and regulatory hurdles associated with new treatment approvals. Furthermore, the rarity of CHI can lead to limited market size, discouraging some pharmaceutical companies from investing in research and development. To overcome these limitations, businesses should focus on innovation in diagnostics and non-invasive treatment options, possibly driven by AI and big data analytics, which can enhance clinical outcomes and cost-efficiency. Additionally, fostering patient advocacy and engagement can aid in raising awareness and encouraging government policies to support market growth. The nature of the market is niche but evolving, with a critical emphasis on research and partnerships which can leverage precision medicine to offer more targeted, effective, and customizable treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 182.53 million
Estimated Year [2024] USD 192.20 million
Forecast Year [2030] USD 267.64 million
CAGR (%) 5.61%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Congenital Hyperinsulinism Treatment Market

The Congenital Hyperinsulinism Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in prevalence of congenital hyperinsulinism disease
    • Government initiatives promoting congenital hyperinsulinism diagnosis
  • Market Restraints
    • Limited reimbursement available for congenital hyperinsulinism
  • Market Opportunities
    • Ongoing R&D for advancing treatment of congenital hyperinsulinism
    • Emerging approval of congenital hyperinsulinism treatments
  • Market Challenges
    • Diagnostic challenges and possible complications of the treatment

Porter's Five Forces: A Strategic Tool for Navigating the Congenital Hyperinsulinism Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Congenital Hyperinsulinism Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Congenital Hyperinsulinism Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Congenital Hyperinsulinism Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Congenital Hyperinsulinism Treatment Market

A detailed market share analysis in the Congenital Hyperinsulinism Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Congenital Hyperinsulinism Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Congenital Hyperinsulinism Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Congenital Hyperinsulinism Treatment Market

A strategic analysis of the Congenital Hyperinsulinism Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Congenital Hyperinsulinism Treatment Market, highlighting leading vendors and their innovative profiles. These include Crinetics Pharmaceuticals, Inc., Eiger Biopharmaceuticals Inc., Hanmi Pharmaceutical Company, Hua Medicine (Shanghai) Co., Ltd., Novartis AG, Rezolute, Inc., Rhythm Pharmaceuticals, Inc., Twist Bioscience Corporation, Xeris Biopharma Holdings, Inc., XOMA Corporation, and Zealand Pharma A/S.

Market Segmentation & Coverage

This research report categorizes the Congenital Hyperinsulinism Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication Type, market is studied across Atypical Congenital Hyperinsulinism, Diffuse Congenital Hyperinsulinism, and Focal Congenital Hyperinsulinism.
  • Based on Treatment, market is studied across Dietary Management, Drugs, and Surgical Intervention. The Drugs is further studied across Diazoxide, Glucagon, Nifedipine, and Octreotide.
  • Based on Route of Administration, market is studied across Oral and Parenteral.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on End-Users, market is studied across Ambulatory Surgery Centers, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in prevalence of congenital hyperinsulinism disease
      • 5.1.1.2. Government initiatives promoting congenital hyperinsulinism diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement available for congenital hyperinsulinism
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D for advancing treatment of congenital hyperinsulinism
      • 5.1.3.2. Emerging approval of congenital hyperinsulinism treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Diagnostic challenges and possible complications of the treatment
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Indication Type: Need for a more personalized approach to treat Atypical CHI
    • 5.2.2. End-Users: Need for a diverse range of treatments for congenital hyperinsulinism in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Congenital Hyperinsulinism Treatment Market, by Indication Type

  • 6.1. Introduction
  • 6.2. Atypical Congenital Hyperinsulinism
  • 6.3. Diffuse Congenital Hyperinsulinism
  • 6.4. Focal Congenital Hyperinsulinism

7. Congenital Hyperinsulinism Treatment Market, by Treatment

  • 7.1. Introduction
  • 7.2. Dietary Management
  • 7.3. Drugs
    • 7.3.1. Diazoxide
    • 7.3.2. Glucagon
    • 7.3.3. Nifedipine
    • 7.3.4. Octreotide
  • 7.4. Surgical Intervention

8. Congenital Hyperinsulinism Treatment Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Oral
  • 8.3. Parenteral

9. Congenital Hyperinsulinism Treatment Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies

10. Congenital Hyperinsulinism Treatment Market, by End-Users

  • 10.1. Introduction
  • 10.2. Ambulatory Surgery Centers
  • 10.3. Hospitals
  • 10.4. Specialty Clinics

11. Americas Congenital Hyperinsulinism Treatment Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Congenital Hyperinsulinism Treatment Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Congenital Hyperinsulinism Treatment Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. C-Path and Congenital Hyperinsulinism International Announce Data Sharing Agreement
    • 14.3.2. Zealand Pharma Submits New Drug Application to US FDA for Dasiglucagon In Congenital Hyperinsulinism
    • 14.3.3. Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Crinetics Pharmaceuticals, Inc.
  • 2. Eiger Biopharmaceuticals Inc.
  • 3. Hanmi Pharmaceutical Company
  • 4. Hua Medicine (Shanghai) Co., Ltd.
  • 5. Novartis AG
  • 6. Rezolute, Inc.
  • 7. Rhythm Pharmaceuticals, Inc.
  • 8. Twist Bioscience Corporation
  • 9. Xeris Biopharma Holdings, Inc.
  • 10. XOMA Corporation
  • 11. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. CONGENITAL HYPERINSULINISM TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. CONGENITAL HYPERINSULINISM TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CONGENITAL HYPERINSULINISM TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CONGENITAL HYPERINSULINISM TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ATYPICAL CONGENITAL HYPERINSULINISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIFFUSE CONGENITAL HYPERINSULINISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY FOCAL CONGENITAL HYPERINSULINISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIETARY MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DIAZOXIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY GLUCAGON, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY NIFEDIPINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY OCTREOTIDE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SURGICAL INTERVENTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY INDICATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM CONGENITAL HYPERINSULINISM TREATMENT MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 281. CONGENITAL HYPERINSULINISM TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 282. CONGENITAL HYPERINSULINISM TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023